1. Home
  2. MED vs MGNX Comparison

MED vs MGNX Comparison

Compare MED & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MEDIFAST INC

MED

MEDIFAST INC

HOLD

Current Price

$10.42

Market Cap

120.6M

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$1.88

Market Cap

115.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MED
MGNX
Founded
1980
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
120.6M
115.8M
IPO Year
1996
2013

Fundamental Metrics

Financial Performance
Metric
MED
MGNX
Price
$10.42
$1.88
Analyst Decision
Hold
Hold
Analyst Count
1
5
Target Price
$12.00
$3.20
AVG Volume (30 Days)
246.2K
533.9K
Earning Date
05-20-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$934,842,000.00
$149,962,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
155.26
52 Week Low
$10.10
$0.99
52 Week High
$15.37
$2.49

Technical Indicators

Market Signals
Indicator
MED
MGNX
Relative Strength Index (RSI) 38.24 57.06
Support Level $10.19 $1.62
Resistance Level $12.21 $1.97
Average True Range (ATR) 0.39 0.09
MACD -0.02 0.02
Stochastic Oscillator 28.07 67.47

Price Performance

Historical Comparison
MED
MGNX

About MED MEDIFAST INC

Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. OPTAVIA provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: